Join MySLAS Social

Special Collection

Back to the Future: Therapeutic Targeting of Cancer Cell Metabolism

The April 2017 issue of SLAS Discovery features a special collection of scientific reports that focus on recent advances in metabolic assay development, metabolomics of patient tumors and identification of novel inhibitors.

An introduction by Raymond Gilmour (Discovery Oncology Research, Lilly Research Laboratories, USA) and Susana Velasco (Cell Signaling Therapies, Centro Nacional de Investigaciones Oncológicas (CNIO), Spain) notes that with new tools and technologies in place, cancer metabolism has become an area of renewed focus for both basic research and drug discovery efforts. The ability to link genetics with metabolomics and integrate in vivo biomarker assays offers the opportunity to target cancer metabolism in the era of personalized medicine.

Papers in the special collection include:

  • Identification of New ATG4B Inhibitors Based on a Novel High-Throughput Screening Platform
  • Bioluminescent Assays for Glucose and Glutamine Metabolism: High-Throughput Screening for Changes in Extracellular and Intracellular Metabolites
  • Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study
  • Discovery of Human Intestinal MGAT Inhibitors Using High-Throughput Mass Spectrometry

SLAS publishes two MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

March 22, 2017